Biotech offers investors the rare chance to invest while drugs are candidates for commercialization and before final FDA approval. There is so much biotech activity, real estate experts say there is a shortage of lab space to conduct clinical trials. Alzheimer’s, smoking addiction and Crohn’s are just some of the diseases researched.
Biotech Pharmaceutical Sector Soars
— Statera Biopharma, Inc. (NASDAQ: STAB) is a clinical-stage biopharmaceutical company studying the treatment of patients with acute COVID-19 infection. Investor timing is critical. STAB has filed with the FDA its Phase 1 Clinical Trial protocol for the investigational treatment of long-haul COVID-19.
This is a pilot study of STAB’s drug STAT-205 treatment of long haul COVID-19. Michael K. Handley, CEO, says the company has a vibrant ‘clinical-stage pipeline’ and it has recently submitted to the FDA a Phase 3 clinical trial protocol for its STAT-201 candidate for the treatment of pediatric Crohn’s Disease.
In its STAT-205 study, STAB is researching acute COVID-19 infection. STAB hopes to develop preliminary data from that study this year.
COVID-19 vaccines are just one investor opportunity in biotech pharmaceuticals. Investing in this stock sector can be a profit maker. Statera Biopharma, Inc. (NASDAQ: STAB) is a clinical-stage biopharmaceutical company studying the treatment of patients with acute COVID-19 long-term infection. Place STAB stock on your Watch List as this compelling biotech research continues.
— Moderna, Inc. (NASDAQ: MRNA) rather than pursuing research on past diseases, is instead planning to develop new vaccines for future pandemics. Its R&D pipeline also ready includes HIV, cancer, flu and COVID-19 vaccines.
Experimental Lung Cancer Vaccine Is Testing
—BioNTech (NASDAQ: BNTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) together are planning on testing an experimental BioNTech lung cacer vaccine. Both companies have already generated billions of dollars in sales from COVID-19 vaccines. The new experimental combination is a joint effort of the two companies.
— Fresenius Medical Care AG & Co. (NYSE: FMS), the largest dialysis company in the world, is looking forward to a bullish 2022. Analyst firm Morningstar says it is developing R&D to remain at the forefront of the at-home patient market.
New Drugs, Acquired Drugs Helps JAZZ Beat Analyst Projections
— Jazz Pharmaceuticals (NASDAQ: JAZZ) beat analysts’ projections for Q4 due to newly developed drugs and drugs acquired in its takeover of GW Pharmaceuticals. New drugs, such as Sunosi, delivered a 71% jump in sales for shareholders. Another drug acquired in the GW Pharmaceuticals transaction was Sativex. It is a cannabis-based mouth spray that has been approved in Europe but not yet in the US.
Novavax Is Researching A COVID-19 Drug Candidate
— Novavax (NASDAQ: NVAX) is researching a COVID-19 drug candidate, NVX: CoV2373. It has already secured approvals from multiple countries as well as an Emergency Use Listing from the WHO.
Novavax also has reported successful testing of its NanoFlu experimental flu vaccine.
— Eli Lilly and Company (NYSE: LLY) has preliminary research from the U.K. that shows its drug Baricitinib successfully reduces the risk of death in hospitalized COVID-19 patients. The drug was originally developed as a rheumatoid arthritis treatment by Eli Lilly jointly with Incyte Corp.
ETF Options Available As Well
Investors can gain a leveraged option exposure to biotech pharmaceutical stocks by buying ProShares Ulta NASDAQ Biotechnology (NASDAQ: BIB). It is a specialized fund that offers a wide range of stocks in the biotech, pharmaceutical sector and even COVID-19 vaccine makers.
Biotech Stocks Can Pay Off Big
Biotech stocks offer investors drug candidates and innovative research that pays off big when commercially successful.
Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies succeed. Link to more news at https://www.staterabiopharma.com/
Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.